Please join the Crinetics management team for a R&D Day to discuss the Company’s proprietary in-house discovery engine and proven development approach for differentiated endocrine therapies.
The event will highlight Crinetics’ early-stage pipeline strategy and data to deliver sustainable long-term growth, with a focus on:
- NETs and beyond – NDC platform with CRN09682
- TSH antagonist for Graves’ disease and thyroid eye disease (TED)
- SST3 agonist for autosomal dominant polycystic kidney disease (ADPKD)
Date:
June 26, 2025
Time:
9:00 AM EDT
Virtual Meeting:
Note: You must register to be eligible to
participate in the meeting.
REGISTER NOW[/vc_column_text][/vc_column][vc_column width=”1/2″][vc_empty_space][vc_single_image media=”130732″ media_width_percent=”100″ uncode_shortcode_id=”504124″ media_link=”url:https%3A%2F%2Fcrinetics.com%2Fwp-content%2Fuploads%2F2025%2F06%2F2025-Crinetics-RD-Day-Presentation.pdf|title:Crinetics%20Pharmaceuticals%202025%20R%26D%20Day”][/vc_column][/vc_row]